???MannKind has amassed an extensive and thorough active immunotherapy patent portfolio,??? said Dr. Zarling. ???We fully appreciate and understand that ILNI generates remarkably superior immune responses that also can be adjuvanted, and our organizations share a passion to advance the current MKC1106 clinical melanoma, prostate, and other programs.